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Abstract 
Background: The impact of neutropenia in critically ill immunocompromised patients admitted in a context of acute 
respiratory failure (ARF) remains uncertain. The primary objective was to assess the prognostic impact of neutropenia 
on outcomes of these patients. Secondary objective was to assess etiology of ARF according to neutropenia.
Methods: We performed a post hoc analysis of a prospective multicenter multinational study from 23 ICUs belong‑
ing to the Nine‑I network. Between November 2015 and July 2016, all adult immunocompromised patients with ARF 
admitted to the ICU were included in the study. Adjusted analyses included: (1) a hierarchical model with center as 
random effect; (2) propensity score (PS) matched cohort; and (3) adjusted analysis in the matched cohort.
Results: Overall, 1481 patients were included in this study of which 165 had neutropenia at ICU admission (11%). 
ARF etiologies distribution was significantly different between neutropenic and non‑neutropenic patients, main 
etiologies being bacterial pneumonia (48% vs 27% in neutropenic and non‑neutropenic patients, respectively). Initial 
oxygenation strategy was standard supplemental oxygen in 755 patients (51%), high‑flow nasal oxygen in 165 (11%), 
non‑invasive ventilation in 202 (14%) and invasive mechanical ventilation in 359 (24%). Before adjustment, hospital 
mortality was significantly higher in neutropenic patients (54% vs 42%; p = 0.006). After adjustment for confounder 
and center effect, neutropenia was no longer associated with outcome (OR 1.40, 95% CI 0.93–2.11). Similar results 
were observed after matching (52% vs 46%, respectively; p = 0.35) and after adjustment in the matched cohort (OR 
1.04; 95% CI 0.63–1.72).
Conclusion: Neutropenia at ICU admission is not associated with hospital mortality in this cohort of critically ill 
immunocompromised patients admitted for ARF. In neutropenic patients, main ARF etiologies are bacterial and fun‑
gal infections.
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea‑
tivecommons.org/licenses/by/4.0/.
Introduction
Therapeutic advances in oncology and hematology 
have led to improved survival in patients with cancer 
[1–3], particularly in the sickest subgroups of patients 
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treated with mechanical ventilation or vasopressors 
[4]. This effect seems to be also pronounced for neutro-
penic patients. Neutropenia is present in approximately 
one-third of critically ill cancer patients. Neutropenia 
is a complex time-dependent [5] and a biphasic immu-
nosuppression state in which the period of neutropenia 
and neutropenia recovery represents high-risk time for 
sepsis, acute respiratory failure (ARF), use of stimulat-
ing factors (e.g., G-CSF), pre-engraftment and engraft-
ment syndromes [6]. Prognostic impact of neutropenia 
remains controversial, particularly in high-risk situa-
tions such as ARF, as there are sparse data on critically ill 
immunocompromised population [7–11]. In immuno-
compromised patients with ARF, failure to identify etio-
logical diagnosis is associated with worse outcome [8, 
12]. A standardized approach (the DIRECT approach) 
can be used to assess the cause of ARF [13–15]. Using 
this tool, previous studies suggest neutropenic patients 
with ARF have a high risk of bacterial or fungal infec-
tion when compared to other immune defects [15]. These 
data are, however, recovered in a single-center study and 
external validity of these findings is needed.
The primary objective of this study was to assess prog-
nostic impact of neutropenia on hospital mortality in 
critically ill patients with immune defect and ARF. Sec-
ondary objective was to assess whether neutropenia was 
associated with specific etiologies.
Patients and methods
This study is a preplanned ancillary analysis of the pro-
spective multicenter multinational Efraim study [8] 
coordinated by the Grrr-OH (Groupe de Recherche en 
Réanimation Respiratoire en Onco-Hématologie) and 
conducted by the Nine-I (Caring for critically ill immu-
nocompromised patients) network. Initially, 1611 immu-
nocompromised adults admitted to the ICU for ARF 
were included from 68 ICUs in 16 countries [8]. After 
IRB approval, each participating ICU prospectively 
included patients between November 2015 and July 2016. 
Inclusion criteria were age (≥ 18 years), acute hypoxemic 
respiratory failure  (PaO2 < 60  mmHg or  SpO2 < 90% on 
room air, or tachypnea > 30/min, or labored breathing or 
respiratory distress or dyspnea at rest or cyanosis), need 
for more than 6 L/min oxygen, respiratory symptom 
duration less than 72  h and non-AIDS-related immune 
deficiency defined as hematologic malignancy or solid 
tumor (active or in remission for less than 5 years, includ-
ing recipients of autologous or allogeneic stem cell trans-
plantation), solid organ transplant, long-term (> 30 days) 
or high-dose (> 1  mg/kg/day) steroids, or any immuno-
suppressive drug for more than 30  days. Patients with 
postoperative acute respiratory failure (within 6  days of 
surgery), those admitted after a cardiac arrest, patients 
admitted only to secure bronchoscopy, and patients/
surrogates who declined study participation were not 
included. Patients were included in this analysis if leuco-
cytes count on ICU admission was available and if hos-
pital mortality was reported. Neutropenia was defined 
as a neutrophil count (or if missing as a white blood cell 
count) lower than 1 G/L at ICU admission. A patient was 
considered to be neutropenic only if he had neutropenia 
at ICU admission.
Data collection
Patient demographic, immunologic (oncologic, hema-
tologic, drugs, etc.), neutropenia, hematopoietic stem 
cell transplant, others comorbidities, functional sta-
tus (ECOG performance status—Eastern Cooperative 
Oncology Group), ARF details (cause, diagnostic investi-
gations, initial oxygen strategy—non-invasive ventilation 
[NIV], high-flow nasal oxygen [HFNO], standard oxygen 
therapy, invasive mechanical ventilation, and ARF man-
agement), critical care treatments and outcomes were 
collected by each participating institution, as previously 
described [7, 8]. All management decisions were made by 
the clinical teams of each institution according to their 
standard of practice. All diagnoses were reviewed by two 
study investigators for coherence and for alignment with 
established definitions [8].
Statistical analysis
Quantitative variables were described as median (inter-
quartile range [IQR]) and were compared between 
groups using the non-parametric Wilcoxon rank-sum 
test. Qualitative variables were described as frequency 
(percentages) and were compared between groups using 
Fisher’s exact test.
Hierarchical models were used to assess factors inde-
pendently associated with hospital mortality. First, 
logistic regression was performed for variable selection. 
We used conditional stepwise regression with 0.2 as the 
critical p value for entry into the model, and 0.1 as the 
p value for removal. It was planned a priori to test influ-
ence of neutropenia in the final model, and even if this 
variable had not been selected. Interactions and correla-
tions between the explanatory variables were carefully 
checked. Continuous variables for which log-linearity 
was not confirmed were transformed into categorical 
variables according to median or IQR. The final models 
were assessed by calibration, discrimination, and rel-
evancy. Residuals were plotted, and the distributions 
inspected. A hierarchical model was then performed 
using variables previously selected along with center as 
random effect on the intercept. This model adjusting for 
clustering effect was planned a priori to be main result 
of the analysis. Same validation methods were used as 
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previously. Adjusted odds ratios (OR) of variables present 
in the final model are presented with their 95% confi-
dence intervals.
In a sensitivity analysis, a double adjustment was per-
formed. First a matching was performed according to 
risk factor to exhibit neutropenia at ICU admission. A 
propensity score (PS) matched analysis was conducted 
comparing neutropenic to non-neutropenic patients. 
Variables for t the PS model were selected according to 
their statistical association with neutropenia (p value 
entry threshold < 0.2) and included age, gender, immune 
defect, hematopoietic stem cell transplantation (HSCT), 
kidney comorbidity, ARF diagnosis, mechanical ven-
tilation, use of vasopressors, and renal replacement 
treatment. Case-matching was conducted using a 1:1 
matching procedure without replacement and according 
to the nearest neighbor method. Adequacy of the match-
ing procedure was assessed by plotting PS across two 
groups and then assessing differences across groups for 
considered variables using standardized mean difference. 
Univariate analysis was performed and a logistic regres-
sion model was then performed, including variables that 
matched poorly or were unmatched [standardized mean 
difference (SMD) above 0.5]. A mixed model was then 
performed using unmatched variables associated with 
mortality in the matched cohort, center being included as 
a random effect on the intercept. As a sensitivity analysis, 
this analysis was run forcing variables with SMD above 
0.2 in the model.
Kaplan–Meier graphs were used to express the prob-
ability of death from inclusion to hospital discharge, 
censored at day 90. Influence of neutropenia status was 
assessed by the log-rank test. Statistical analyses were 
performed with R statistical software, version 3.4.3 (avail-
able online at https ://www.r-proje ct.org/) and packages 
‘Survival’, ‘MatchIt’, ‘lme4’, and ‘lmerTest’. A p value < 0.05 
was considered significant.
Results
Overall, among the 1611 patients included in the 
EFRAIM study, 1481 patients had mortality and white 
cell count data available and were included in this study 
(Fig.  1). Median age was 64  years [IQR 55–72] and 613 
patients (39.7%) were female. Median SOFA score was 
7 [4–10] and performance status was 1 [0–3]. The most 
common immune defect was hematological malignancy 
(HM) in 533 patients (36%), solid tumor in 473 (32%), 
systemic disease in 155 (10.5%), and the use of immuno-
suppressive drugs in 117 (8%). Neutropenia at admission 
was observed in 165 patients (11%). Among neutropenic 
N=1.611 immunocompromised paents
admied to 62 ICUs in 16 countries for acute 
respiratory failure (ARF)
130 paents with missing data 
on outcome and/or leucocyte
1481 paents had available 
outcome and leucocyte data and 
were included in this study. 
165 Neutropenic paents with 
ARF (11%) 
1316 Non-neutropenic paents 
with ARF (89%) 
Fig. 1 Study flowchart
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patients, more than 95% (n = 157) of the patients pre-
sented at ICU admission with profound neutropenia 
(neutrophils < 0.5 G/L) and 93% (n = 153) with severe 
neutropenia (neutrophils < 0.1 G/L). Initial oxygenation 
strategy was standard oxygen in 755 patients (51%), high-
flow nasal oxygen in 165 (11%), non-invasive mechani-
cal ventilation in 202 (14%), and invasive mechanical 
ventilation in 359 (24%). At ICU admission neutropenic 
patients presented with a higher SOFA score than non-
neutropenic patients (10 (7–12) vs 6 (4–10), respectively, 
p < 0.001). Neutropenic patients were more frequently 
treated with vasopressors than non-neutropenic patients 
(117 (70.9%) vs 732 (55.6%), respectively, p < 0.001), with 
renal replacement therapy (RRT) (43 (26.1%) vs 208 
(15.8%), respectively, p = 0.001), and distribution of res-
piratory support at ICU admission was also different 
between groups (p = 0.017, Table  1). During ICU stay, 
cumulative incidence of invasive mechanical ventilation 
was not different between groups (p = 0.28, Additional 
file 1: Fig. S1). Before adjustment, hospital mortality rate 
was significantly higher in neutropenic patients (54% vs 
42% in non-neutropenic patients; p = 0.006) (Table  1). 
After adjustment for confounders and center effect, neu-
tropenia was no longer associated with outcome (OR 
1.40, 95% CI 0.93–2.11), RRT, vasopressor use, and older 
age being independently associated with higher hospital 
mortality (Additional file 2: Table S1; Hosmer–Lemeshow 
goodness of fit: p = 0.12; AUC 0.72; 95% CI 0.70–0.74).
After propensity score (PS) matching, 148 patients in 
each cohort were compared (Table  2, Fig.  2). Standard-
ized mean differences suggest adequate adjustment on 
considered variables except for stem cell transplantation 
(Additional file 3: Fig. S2, SMD 0.25). Hospital mortality 
in the matched cohort did not differ between neutropenic 
and non-neutropenic patients (52% vs 46%, respectively; 
p = 0.35) (Table 2, Fig. 2).
In the analysis adjusted for confounders and center 
effect, there was no association between neutropenia 
and hospital survival (OR 1.04; 95% CI 0.63–1.72; Addi-
tional file  4: Table  S2; Hosmer–Lemeshow goodness of 
fit: p = 0.58; AUC 0.68; 95% CI 0.61–0.74).
Acute respiratory failure etiologies distribution was 
significantly different between neutropenic and non-
neutropenic patients, main etiologies being bacterial 
pneumonia (48% vs 27%), invasive fungal infection (10% 
vs 7%), and Pneumocystis jiroveci pneumonia (2% vs 4%), 
other diagnosis (32% vs 56%), and undetermined etiology 
(8% vs 11%), respectively (p < 0.001) (Table 1, Additional 
file  5: Fig. S3). Microbiologically documented infection 
also displayed a different profile in neutropenic patients 
(Table  3, p = 0.04). In addition, influenza (15%) or non-
influenza (28%) viral infections as well as cardiogenic 
edema (24%) appeared to be frequent other situations in 
neutropenic patients, whereas tumor infiltrations were 
rarely diagnosed (4%) (Additional file 6: Table S3).
Discussion
In this large cohort study, neutropenia was not associ-
ated with outcome in critically ill immunocompromised 
patients with ARF after adjustment for confounders. Eti-
ology of ARF was however significantly different between 
neutropenic and non-neutropenic patients, with neutro-
penia being associated with a higher rate of bacterial and 
fungal infection.
Although neutropenia remains associated with a poor 
outcome in general ICU populations [16], several recent 
studies have not shown an association between neu-
tropenia and outcomes of critically ill cancer patients 
[7, 17]. Neutropenia remains an accepted side effect of 
most treatments administered to hematological patients 
[18]. Neutropenia is also associated with various com-
plications including severe sepsis [19, 20], acute res-
piratory failure [21], and specific adverse effects such 
as neutropenic enterocolitis [22]. Although these side 
effects are likely to influence the outcome of critically 
ill patients, results of studies in this field remain con-
troversial. In a recent multicenter observational study 
including 289 critically ill neutropenic cancer patients, 
the hospital mortality rate was 55%, however neutrope-
nia was not associated with outcome after adjustment 
for confounder [10]. Independent factors associated with 
hospital mortality were age, allogeneic HSCT, invasive 
mechanical ventilation, RRT, microbiologic documenta-
tion; whereas, neutropenic enterocolitis was associated 
with survival. In contrast, a recent individual patient data 
meta-analysis including 7512 critically ill cancer patients 
concluded that neutropenia was independently associ-
ated with increased risk of death of 10% [4]. In the pre-
sent study, neutropenia was not associated with outcome 
after adjustment for confounders and propensity score 
analysis. Importantly, after matching, neutropenia, when 
associated with acute respiratory failure, was not a risk 
factor for hospital mortality regardless of the underlying 
immunosuppression. However, crude hospital mortality 
was 54% underlining that neutropenia and acute respira-
tory failure were associated with a high morbidity and 
mortality.
Neutropenia was found to be associated with higher 
severity and rate of organ dysfunction. This might be 
related to a longer delay to ICU admission [23]. Hence, 
although HFNO was used more frequently in neu-
tropenic patients at ICU admission, use of invasive 
mechanical ventilation was found to be required simi-
larly in neutropenic and non-neutropenic patients during 
ICU stay. Whether the presence of neutropenia at ICU 
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admission might modify treatment strategy during ICU 
may therefore deserve to be further evaluated.
An important point of the Efraim study was the associ-
ation between of undiagnosed etiology of ARF and higher 
hospital mortality [8]. In our study, we found a low rate 
of undetermined etiological diagnosis in the subgroup of 
neutropenic patients (8%), identification of etiology being 
achieved mainly by non-invasive diagnostic strategies. 
This highlights the importance of a relevant diagnostic 
work-up for high-risk patients admitted to ICU occurring 
Table 1 Characteristics of neutropenic vs non-neutropenic patients
SOFA Sequential Organ Failure Assessment score, ECOG-PS Eastern Cooperative Oncology Group-Performance Status, BAL bronchoalveolar lavage, ICU intensive care 
unit
Non-neutropenic (n = 1316) Neutropenic (n = 165) p value
Age (median [IQR]) 65 (55–72) 59 (45.5–67) < 0.001
Female 529 (40.5) 56 (34.1) 0.14
SOFA (median [IQR]) 6 (4–10) 10 (7–12) < 0.001
ECOG‑PS (median [IQR]) 1 (1–2) 1 (1–2) 0.51
Organ transplantation 125 (10.6) 3 (1.9) 0.001
Leucocytes count at ICU admission(G/L) 13 (6–27) 0.00 (0.00–0.00) < 0.001
Neutrophils count at ICU admission(G/L) 10(4–23) 0.00 (0.00–0.00) < 0.001
Hematopoietic cell transplant (HCT) < 0.001
 No HCT 1139 (86.6) 107 (64.8)
 Autologous HCT 68 (5.2) 26 (15.8)
 Allogeneic HCT 109 (8.3) 32 (19.4)
Immune defect < 0.001
 Acute leukemia 167 (12.7) 70 (42.4)
 Chronic leukemia 68 (5.2) 6 (3.6)
 Hodgkin disease 28 (2.1) 5 (3)
 Drug‑induced immunosuppression 105 (8) 2 (1.2)
 Myeloma 122 (9.3) 13 (7.9)
 Non‑Hodgkin lymphoma 138 (10.5) 33 (20)
 Other 103 (7.8) 16 (9.7)
 Solid tumor 433 (32.9) 19 (11.5)
 Systemic 152 (11.6) 1 (0.6)
Comorbidities
 Diabetes 266 (20.8) 17 (10.8) 0.004
 Kidney 209 (16.2) 9 (5.6) 0.001
 Cirrhosis 48 (3.7) 4 (2.5) 0.57
Respiratory support 0.02
 High‑flow nasal oxygen 138 (10.5) 27 (16.4)
 Non‑invasive ventilation 182 (13.8) 20 (12.1)
 O2 664 (50.5) 91 (55.2)
 Mechanical ventilation 332 (25.2) 27 (16.4)
 Vasopressors 732 (55.6) 117 (70.9) < 0.001
 Renal replacement therapy 208 (15.8) 43 (26.1) 0.001
Acute respiratory failure diagnosis (%) < 0.001
 Bacterial 356 (27.1) 79 (47.9)
 Fungal 74 (5.6) 17 (10.3)
 Other 691 (52.5) 53 (32.1)
 Pneumocystis 48 (3.6) 3 (1.8)
 Unknown 147 (11.2) 13 (7.9)
 No BAL use 823 (62.5) 108 (65.5) 0.52
 ICU mortality 417 (31.7) 72 (43.6) 0.003
 Hospital mortality 557 (42.2) 89 (54) 0.006
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in specialized centers. During neutropenia, phagocytosis, 
chemotaxis and the oxidative capacities of granulocytes 
are affected thus predisposing patients to bacterial infec-
tions and invasive fungal infections (IFI) [14]. Our study 
showed, in a selected population of immunosuppressed 
patients admitted to ICU for ARF with neutropenia, the 
main diagnosis was bacterial and/or fungal infections. 
In neutropenic patients, non-fermenting Gram-negative 
bacilli such as Pseudomonas as well as enterobacteriaceae 
such as Klebsiella were frequently documented in con-
trast to Staphylococcus aureus infections [24]. Our results 
are strongly in accordance with the DIRECT approach, in 
which the "I" designates the type of immunosuppression 
and represents an essential step in patient management 
as it suggests for neutropenic patients, first to preferen-
tially suspect bacterial or fungal infections [13, 14, 24], 
second to encourage a non-invasive diagnostic strategy 
with bronchoalveolar lavage used only in selected group 
of patients [25], and third to start empirical anti-micro-
bial treatment targeting non-fermenting Gram-negative 
bacilli [13, 20, 24] and/or the most frequent IFIs such as 
invasive pulmonary aspergillosis [26]. The detection of 
respiratory viruses in the upper airway is common in crit-
ically ill hematologic patients [27]. In patients with ARF, 
respiratory virus detection was independently associated 
with ICU mortality [27]. Interestingly, influenza viral 
Table 2 Characteristics of neutropenic vs non-neutropenic patients after propensity score matching
SOFA Sequential Organ Failure Assessment score, BAL bronchoalveolar lavage
Non-neutropenic (n = 148) Neutropenic (n = 148) p value
Age (median [IQR]) 55.55 (15.85) 55.75 (14.12) 0.91
Female (%) 54 (36.5) 49 ( 33.1) 0.63
SOFA (median [IQR]) 8.00 [5.00, 10.00] 10.00 [7.00, 12.00] < 0.001
Hematopoietic cell transplant (HCT) 0.07
 No (HCT) 107 (72.3) 97 (65.5)
 Autologous HCT 12 (8.1) 25 (16.9)
 Allogeneic HCT 29 (19.6) 26 ( 17.6)
Immune defect (ID) 0.94
 Acute leukemia 66 (44.6) 62 (41.9)
 Chronic leukemia 2 (1.4) 6 (4.1)
 Hodgkin disease 7 (4.7) 5 (3.4)
 Drug‑induced immunosuppression 1 (0.7) 1 (0.7)
 Myeloma 13 (8.8) 13 (8.8)
 Non‑Hodgkin lymphoma 31 (20.9) 32 (21.6)
 Other 10 ( 6.8) 11 (7.4)
 Solid tumor 16 (10.8) 17 (11.5)
 Systemic 2 ( 1.4) 1 (0.7)
 Kidney comorbidity 13 ( 8.8) 9 (6.1) 0.51
Respiratory support 0.73
High‑flow nasal oxygen 28 (18.9) 24 (16.2)
Non‑invasive ventilation 13 ( 8.8) 16 (10.8)
O2 78 (52.7) 84 (56.8)
Mechanical ventilation 29 (19.6) 24 (16.2)
Vasopressors 115 (77.7) 103 (69.6) 0.15
Renal replacement therapy 42 (28.4) 39 (26.4) 0.79
Acute respiratory failure diagnosis 0.82
 Bacterial 69 (46.6) 73 (49.3)
 Fungal 15 (10.1) 16 (10.8)
 Other 49 (33.1) 44 (29.7)
 Pneumocystis 1 ( 0.7) 3 (2.0)
 Unknown 14 ( 9.5) 12 (8.1)
 No BAL use 77 (52.0) 95 (64.2) 0.05
 Hospital mortality 68 (45.9) 77 (52.0) 0.35
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infection in immunosuppressed patients is also associ-
ated with ICU mortality [28]. In neutropenic patients, the 
viral risk is currently unknown. We have shown in this 
study that viral infections were also frequent in neutro-
penic patients with ARF, however molecular multiplex 
respiratory virus techniques are not standardized [27]. 
The clinical implications of these results remain not only 
to be evaluated in terms of empiric anti-microbial treat-
ment, but also in terms of diagnostic strategy [25, 29].
This study has several limitations. First, neutropenia 
being a time-dependent parameter, this characteristic 
was evaluated at ICU admission to avoid influence of 
competing events on findings. Along this line, the impact 
of neutropenia recovery on changes in respiratory sta-
tus could not be assessed due to the lack of data on this 
point. Although our results are robust with regard to the 
prognostic influence of neutropenia at ICU admission, 
no conclusion can be drawn with regard to the prognos-
tic influence of neutropenia occurring during ICU stay. 
In this line, influence of neutropenia duration was not 
assessed either before ICU admission or during ICU stay 
and could have influenced our findings. In addition, man-
agement of neutropenic patients may vary across centers 
and some center-specific management strategies or ICU 
admission policies might have influenced our findings. 
However, the analysis was performed using a hierarchi-
cal model that should have partly adjusted for clustering 
effect. Unfortunately, the ratio of patients who died in a 
context of therapeutic limitation was not available in our 
data collection. However, the majority of neutropenic 
patients admitted to intensive care are admitted in a con-
text of recent chemotherapy, in which context an ICU full 
code management strategy is often implemented. Lastly, 
lack of statistical power may have explained the lack of 
association between neutropenia and outcome [30, 31]. 
Our findings were, however, robust and persistent after 
sensitivity analysis suggesting that the impact of neutro-
penia on the prognosis was less than the degree of organ 
dysfunction and severity or underlying etiology of ARF.
Conclusion
Neutropenia at ICU admission is not associated with 
hospital mortality in this cohort of critically ill immuno-
compromised patients admitted for ARF. In neutropenic 
patients, the main causes of ARF were bacterial and fun-
gal infections.
Fig. 2 Hospital survival after propensity score matching comparing 148 neutropenic patients with 148 non‑neutropenic patients (Kaplan–Meier 
curve)
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ment of Critical Care and Graduate Program in Translational Medicine, D’Or 
Institute for Research and Education, Programa de Pós‑Graduação Em Clínica 
Médica, Rio de Janeiro, Brazil. 6 CIBERES, Instituto de Salud Carlos III, Barcelona, 
Spain. 7 Clinical Research/Epidemiology In Pneumonia and Sepsis (CRIPS), 
Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain. 8 Anesthesiology 
Department, Clinical Research in ICU, CHU Nîmes, University Montpellier, 
Nîmes, France. 9 Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, 
MN, USA. 10 Division of Pulmonary and Critical Care, Penn State University Col‑
lege of Medicine, Hershey, PA, USA. 11 Department of Intensive Care, Hôpital 
Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium. 12 Department 
of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organiza‑
tion (MICRO), St. James’s Hospital, Dublin, Ireland. 13 Department of Clinical 
Medicine, Trinity College, Wellcome Trust‑HRB Clinical Research Facility, St 
James Hospital, Dublin, Ireland. 14 Department of Anesthesiology and Inten‑
sive Care Medicine and Institute for Medical Humanities, 1St Faculty of Medi‑
cine, Charles University in Prague and General University Hospital, Prague, 
Czech Republic. 15 Department of Medicine and Interdepartmental Division 
of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, 
ON, Canada. 16 Dept of Anesthesia Intensive Care and Emergency Medicine, 
Fondazione Policlicnico Universitario A.Gemelli IRCCS. Università Cattolica del 
Sacro Cuore, Rome, Italy. 17 Department of Medical Intensive Care Medicine, 
University Hospital of Angers, Angers, France. 18 Department of Emergencies 
and Critical Care, Oslo University Hospital, Oslo, Norway. 19 Division of Intensive 
Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medi‑
cine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 
20 Department of Critical Care, University Medical Center Groningen, Gronin‑
gen, The Netherlands. 21 Department of Anesthesiology I, Herlev University 
Hospital, Herlev, Denmark. 22 Medical ICU, Cochin Hospital, Assistance Pub‑
lique‑Hôpitaux de Paris and University Paris Descartes, Paris, France. 23 King’s 
Table 3 Bacterial infectious diagnoses
Non-
neutropenic 
(n = 356)
Neutropenic 
(n = 79)
p value
0.044
Gram‑negative bacteria
 Pseudomonas 31 (9%) 14 (18%)
 Klebsiella 33 (9%) 14 (18%)
 Escherichia coli 40 (11%) 14 (18%)
 Enterobacter 18 (5%) 3 (4%)
 Stenotrophomonas 3 (1%) 3 (4%)
 Legionella 4 (1%) 2 (3%)
 Branhamella catarrhalis 6 (2%) 2 (3%)
 Acinetobacter 7 (2%) 1 (1%)
 Haemophilus influenzae 13 (4%) 1 (1%)
 Campylobacter jejuni 0 (0%) 1 (1%)
 Citrobacter 1 (0.5%) 1 (1%)
 Proteus 4 (1%) 0
 Hafnia alvei 3 (1%) 0
 Morganella 3 (1%) 0
 Serratia 3 (1%) 0
 Salmonella 2 (0.5%) 0
 Neisseria meningitidis 2 (0.5%) 0
 Bacteroides 1 (0.5%) 0
 Bordetella hinzii 1 (0.5%) 0
Gram‑positive bacteria
 Coagulase-negative staphy-
lococci
49 (14%) 9 (11%)
 Enterococcus 31 (9%) 6 (8%)
 Staphylococcus aureus 49 (14%) 4 (5%)
 Streptococcus 11 (3%) 2 (3%)
 Streptococcus pneumoniae 34 (10%) 1 (1%)
 Actinomyces 3 (1%) 0
 Clostridium 1 (0.5%) 0
Others
 Mycoplasma 3 (1%) 0
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College Hospital, London SE5 9RS, UK. 24 Terapia Intensiva, Hospital Maciel, 
Montevideo, Uruguay. 25 Intensive Care Department, University of Southern 
Denmark, Odense, Denmark. 26 Department of Anaesthesia and Intensive 
Care, Odense University Hospital, Odense, Denmark. 27 Medical Intensive Care 
Unit, Hôtel Dieu‑HME University Hospital of Nantes, Nantes, France. 
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